Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

Designed for advanced Parkinson’s with poorly controlled motor fluctuations, the infusion delivers steadier levodopa exposure than pills via continuous subcutaneous dosing.

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

A 24-hour continuous subcutaneous infusion of foslevodopa/foscarbidopa improved Parkinson's disease (PD) motor symptoms during all waking hours for patients with ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

KORU Medical Systems, Inc. KRMD has made a strategic move in its pursuit of expanding its footprint in the realm of large-volume subcutaneous infusion. The company announced a collaboration with a ...

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World ...